Video

Dr. Dreicer discusses efficacy of androgen receptor pathway inhibitors in mCSPC

Video Player is loading.
Current Time 0:00
Duration 1:32
Loaded: 0%
Stream Type LIVE
Remaining Time 1:32
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Robert Dreicer, MD, explains how intensifying treatment through the combination of androgen-deprivation therapy and androgen receptor pathway inhibitors (eg, abiraterone acetate [Zytiga], enzalutamide [Xtandi], and apalutamide [Erleada]) has improved outcomes in patients with metastatic castration-sensitive prostate cancer. Dreicer is deputy director, UVA Cancer Center, director, Solid Tumor Oncology in the Division of Hematology/Oncology, and a professor of medicine and urology, University of Virginia Health System.

    © 2025 MJH Life Sciences

    All rights reserved.